BUSINESS WIREMay 12 2023 Sarepta Therapeutics Inc NASDAQ SRPT the leader in precision genetic medicine for rare diseases today announced that the US Food and Drug Administration FDA Cellular Tissue and Gene Therapies Advisory Committee CTGTAC voted 8 to 6 in support of accelerated approval of SRP9001 delandistrogene moxeparvovec for the treatment of ambulatory patients with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene